Page last updated: 2024-09-05

erlotinib hydrochloride and Neoplasm Metastasis, Unknown Primary

erlotinib hydrochloride has been researched along with Neoplasm Metastasis, Unknown Primary in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Daido, W; Deguchi, N; Fujihara, M; Funaishi, K; Hattori, N; Ishiyama, S; Ohashi, N; Saito, N; Sakano, A; Taniwaki, M; Yamasaki, M	1
Greco, FA; Hainsworth, JD; Lane, CM; Murphy, PB; Naot, Y; Spigel, DR; Thompson, DS; Waterhouse, DM	1
Farley, C; Greco, FA; Hainsworth, JD; Shipley, DL; Spigel, DR; Thompson, DS	1

Trials

2 trial(s) available for erlotinib hydrochloride and Neoplasm Metastasis, Unknown Primary

Article	Year
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. The oncologist, 2009, Volume: 14, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult	2009
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Quinazolines; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A	2007

Article

Year

Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.

The oncologist, 2009, Volume: 14, Issue:12

Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult

2009

Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Quinazolines; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A

2007

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Neoplasm Metastasis, Unknown Primary

Article	Year
Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report. Medicine, 2018, Volume: 97, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Neoplasms, Unknown Primary; Protein Kinase Inhibitors	2018